The global arthropod-borne viral infections testing market is set for steady growth, with its value projected to rise from USD 1.9 billion in 2022 to USD 1.3 billion by the end of 2029. This expansion corresponds to a compound annual growth rate (CAGR) of 5.6% during the forecast period, reflecting the increasing demand for diagnostic solutions for diseases transmitted by arthropods, such as mosquitoes and ticks.
Arthropod-borne viral infections, including diseases like Zika, dengue, and West Nile virus, continue to pose significant public health threats worldwide. The growing incidence of these diseases, especially in tropical and subtropical regions, has led to an increased need for reliable and efficient diagnostic testing. Advances in molecular and serological diagnostic techniques are also driving market growth by enabling faster and more accurate detection of these viral infections.
Key factors propelling the market include rising global awareness about arthropod-borne diseases, improvements in healthcare infrastructure, and increasing investments in diagnostic research. Furthermore, rising travel and climate change are contributing to the spread of these infections, creating a greater demand for effective testing solutions.
As the market evolves, leading diagnostic companies are focusing on the development of innovative testing kits and point-of-care solutions to enhance the efficiency of arthropod-borne viral infections detection. With increasing global health concerns, the market is poised for continued growth and plays a crucial role in advancing global disease surveillance and prevention efforts.
Key Growth Drivers
- Rising Incidence of Arthropod-Borne Diseases: The increasing number of cases related to diseases such as dengue, Zika virus, and chikungunya is driving the demand for effective diagnostic testing.
- Advancements in Diagnostic Technologies: Innovations in testing methods, including RT-PCR and ELISA-based tests, are enhancing the accuracy and speed of diagnosis.
- Government Initiatives: Efforts by governments and health organizations to control and prevent outbreaks are boosting the market for testing solutions.
Market Dynamics
- Testing Methods: The market includes various testing types, with ELISA-based tests holding a significant share due to their effectiveness in diagnosing arbovirus infections.
- End-Use Segments: Public health laboratories are expected to dominate the market, driven by increased investments in surveillance programs and diagnostic capabilities.
Competitive Landscape
Arthropod-borne viral infections testing providers are investing in the research and development of rapid test kits that are effective in diagnosing infections in a short period of time with minimal error.
- In November 2021, Achico, a healthcare technology firm headquartered in Switzerland, announced the development of dengue fever diagnostic kits. This new testing kit would be based on the company’s DNA aptamer technology platform that has proven its efficiency in COVID-19 diagnosis.
Get the Comprehensive Full Report Now
Key Companies Profiled
Thermo Fisher Scientific Inc.; Roche Molecular Systems Inc.; bioMérieux SA; InBios International Inc.; NovaTec Immundiagnostica GmbH; Euroimmun AG (Sub. PerkinElmer); Quest Diagnostics; Certest Biotec S.L.; Response Biomedical Corp.; Chembio Diagnostic Systems Inc.; Abbott Laboratories
Key Segments of Arthropod-borne Viral Infections Testing Industry Survey
by Test Type:
- ELISA-based Tests for Arthropod-borne Viral Infections Testing
- RT-PCR-based Tests for Arthropod-borne Viral Infections Testing
- Immunochromatography Rapid Diagnosis for Arthropod-borne Viral Infections Testing
by End User:
- Arthropod-borne Viral Infections in Testing Hospitals
- Arthropod-borne Viral Infections in Public Health Laboratories
- Arthropod-borne Viral Infections in Diagnostic Centres
- Others
by Region:
- North America Arthropod-borne Viral Infections Testing Market
- Latin America Arthropod-borne Viral Infections Testing Market
- Europe Arthropod-borne Viral Infections Testing Market
- East Asia Arthropod-borne Viral Infections Testing Market
- South Asia & Pacific Arthropod-borne Viral Infections Testing Market
- Middle East & Africa (MEA) Arthropod-borne Viral Infections Testing Market
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
